Venture Capital Vi, L.P.Ver... Net Worth

The estimated Net Worth of Venture Capital Vi, L.P.Ver... is at least $24.2 Million dollars as of 28 August 2024. Venture Ver owns over 221,600 units of Black Diamond Therapeutics Inc stock worth over $22,842,470 and over the last few years Venture sold BDTX stock worth over $1,400,512.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Venture Ver BDTX stock SEC Form 4 insiders trading

Venture has made over 1 trades of the Black Diamond Therapeutics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Venture sold 221,600 units of BDTX stock worth $1,400,512 on 28 August 2024.

The largest trade Venture's ever made was selling 221,600 units of Black Diamond Therapeutics Inc stock on 28 August 2024 worth over $1,400,512. On average, Venture trades about 221,600 units every 0 days since 2024. As of 28 August 2024 Venture still owns at least 3,726,341 units of Black Diamond Therapeutics Inc stock.

You can see the complete history of Venture Ver stock trades at the bottom of the page.

Insiders trading at Black Diamond Therapeutics Inc

Over the last 5 years, insiders at Black Diamond Therapeutics Inc have traded over $26,407,257 worth of Black Diamond Therapeutics Inc stock and bought 10,796,678 units worth $105,501,601 . The most active insiders traders include Ali Behbahani, Rajeev M. Shah, and Capital Management, L.P.Ra .... On average, Black Diamond Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $899,443. The most recent stock trade was executed by Venture Capital Vi, L.P.Ver... on 28 August 2024, trading 221,600 units of BDTX stock currently worth $1,400,512.

What does Black Diamond Therapeutics Inc do?

black diamond therapeutics, inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. its lead product candidate is bdtx-189, an inhibitor of non-canonical and oncogenic mutations of erbb kinases epidermal growth factor receptor (egfr) and tyrosine-protein kinase. the company is also developing allosteric-egfr mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. the company was formerly known as aset therapeutics, inc. and changed its name to black diamond therapeutics, inc. in january 2018. black diamond therapeutics, inc. was founded in 2014 and is headquartered in cambridge, massachusetts.

Complete history of Venture Ver stock trades at Black Diamond Therapeutics Inc

Black Diamond Therapeutics Inc executives and stock owners

Black Diamond Therapeutics Inc executives and other stock owners filed with the SEC include:

• David Epstein,
  President, Chief Executive Officer, Director
• Thomas Leggett,
  Chief Financial Officer
• Christopher Roberts,
  Chief Scientific Officer
• Dr. David M. Epstein Ph.D.,
  Co-Founder, Pres, CEO & Director
• Brent Hatzis-Schoch Esq., J.D.,
  COO & Gen. Counsel
• Samarth Kulkarni,
  Independent Director
• Dr. Rachel Wallach Humphrey M.D., Ph.D.,
  Advisor
• Garry Menzel,
  Independent Director
• Rajeev Shah,
  Independent Director
• Ali Behbahani,
  Independent Director
• Alexander Mayweg,
  Director
• Bradley Bolzon,
  Director
• Fang Ni,
  Chief Business Officer
• Rachel Humphrey,
  Chief Medical Officer
• Karsten Witt,
  Senior Vice President - Non-Clinical Development
• Elizabeth Buck,
  Executive Vice President - Discovery and Translational Services
• Brent Hatzis-Schoch,
  Chief Operating Officer, General Counsel
• Robert Ingram,
  Independent Chairman of the Board
• Tai-An Lin Ph.D.,
  VP & Head of Biology
• Dr. Karsten Witt M.D.,
  Sr. VP of Clinical Devel. & Interim Chief Medical Officer
• Dr. Christopher D. Roberts Ph.D.,
  Advisor
• Erika Jones,
  VP of Fin., Corp. Controller & Principal Accounting Officer
• Dr. Fang Ni Pharm.D.,
  CFO, Principal Financial Officer and Chief Bus. Officer
• Dr. Elizabeth Buck Ph.D.,
  Co-Founder & Chief Scientific Officer
• James E Deerfield Mgmt L.P....,
  
• Sergey Yurasov,
  CHIEF MEDICAL OFFICER
• Shannon Campbell,
  
• Prakash Raman,
  
• Venture Capital Vi, L.P.Ver...,
  
• Biomedical Innovation Maste...,
  10% owner
• Venture Capital Vi, L.P.Ver...,
  
• Erika Jones,
  SEE REMARKS
• Wendy L Dixon,
  
• Growth N Vbb Biotech Ag Bio...,
  
• Kapil Dhingra,
  
• Capital Management, L.P.Ra ...,
  
• Mark A. Velleca,
  PRESIDENT & CEO